Anti-Neprilysin inhibitors are a class of medications that inhibit neprilysin, a zinc-dependent metalloproteinase enzyme that breaks down vasoactive peptides including natriuretic peptides and bradykinin. These medications offer several advantages such as reducing morbidity, mortality and hospitalization rates associated with heart failure.
The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising prevalence of conditions such as heart failure, cardiomyopathy and hypertension where anti-neprilysin inhibitors are used is the major factor driving the growth of anti-neprilysin market. It is estimated that over 6 million Americans suffer from heart failure and around half of them die within 5 years of diagnosis. Increasing risk factors such as obesity, diabetes and aging population has further increased the burden of these conditions globally. Anti-neprilysin inhibitors have demonstrated efficacy in reducing rates of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction. This has resulted in greater adoption of anti-neprilysin drugs and positively impacted the market growth. Ongoing research and clinical trials to expand indication of existing anti-neprilysin drugs as well as development of new molecules in the pipeline are also contributing to market expansion.
SWOT Analysis
Strength: The anti-neprilysin drug class is used for the treatment of heart failure and has the potential to become an important therapeutic area. Some anti-neprilysin inhibitors like sacubitril/valsartan have shown promising results in clinical trials.
Weakness: Developing new anti-neprilysin drugs is an expensive and time-consuming process which requires extensive research and clinical testing. Safety concerns remain regarding drug side effects like hypotension which can limit the patient population.
Opportunity: The growing prevalence of heart failure worldwide coupled with limitations of existing therapies provides scope for effective anti-neprilysin drugs. Launch of innovative formulations can help expand the target population.
Threats: Intense competition from alternative heart failure treatment options and strict regulatory pathway can pose threats. Issues regarding patent cliffs and loss of market exclusivity can negatively impact revenues of leading drugs.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth over the forecast period supported by rising heart failure incidence. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
North America currently dominates the market due to presence of major players and higher adoption of advanced treatment options. The United States contributes significantly to the largest revenue share attributed to well-established healthcare infrastructure and reimbursement policies in the region.
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. These companies are focusing on developing new molecules and formulations to expand indications and target patient population. Various clinical trials are also being conducted to evaluate anti-neprilysin drugs for other conditions like diabetic kidney disease.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
